Estados Unidos · Bolsas y cotizaciones · Nasdaq

Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer

Publicado por Nasdaq · Estados Unidos hace 2 h

(RTTNews) - Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal…

Leer el artículo completo en Nasdaq Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.nasdaq.com)

Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer

También te puede interesar

Worldcoin Drops 13% as Institution Moves 19.7M WLD

Trump's Reverse Nixon Strategy: Bring Russia In, Shut China Out

Are You Earning More or Less Than Others Your Age? New Fed Data Reveals the Answer

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog

Subtropical Storm Josephine heads away from East Coast

Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer

Compartir

También te puede interesar

Worldcoin Drops 13% as Institution Moves 19.7M WLD

Trump's Reverse Nixon Strategy: Bring Russia In, Shut China Out

Are You Earning More or Less Than Others Your Age? New Fed Data Reveals the Answer

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog

Subtropical Storm Josephine heads away from East Coast